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Abstract
Background An increasing number of technologies are obtaining marketing authorisation based on sparse evidence, which 
causes growing uncertainty and risk within health technology reimbursement decision making. To ensure that uncertainty is 
considered and addressed within health technology assessment (HTA) recommendations, uncertainties need to be identified, 
included in health economic models, and reported.
Objective Our objective was to develop the TRansparent Uncertainty ASsessmenT (TRUST) tool for systematically iden-
tifying, assessing, and reporting uncertainties in decision models, with the aim of making uncertainties and their impact on 
cost effectiveness more explicit and transparent.
Methods TRUST was developed by drawing on the uncertainty and risk assessment literature. To develop and validate this 
tool, we conducted HTA stakeholder discussion meetings and interviews and applied it in six real-world HTA case studies 
in the Netherlands and the UK.
Results The TRUST tool enables the identification and categorisation of uncertainty according to its source (transparency 
issues, methodology issues, and issues with evidence: imprecision, bias and indirectness, and unavailability) in each model 
aspect. The source of uncertainty determines the appropriate analysis. The impact of uncertainties on cost effectiveness is 
also assessed. Stakeholders found using the tool to be feasible and of value for transparent uncertainty assessment. TRUST 
can be used during model development and/or model review.
Conclusion The TRUST tool enables systematic identification, assessment, and reporting of uncertainties in health economic 
models and may contribute to more informed and transparent decision making in the face of uncertainty.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-019-00855 -9) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Uncertainty is rife in health technology assessment (HTA), 
which leads to increased complexity in decision making. 
Drug approval processes are typically based on evidence that 
exhibits several limitations [1–3]. These may include, among 
others, a lack of data on a certain relevant health outcome 
(e.g. long-term treatment effectiveness), limited generalisa-
bility of evidence to the decision context, small sample sizes, 
and data immaturity. The result is that health economic 
models used to inform such decisions (further referred to 
as ‘models’) suffer from uncertainty in, for instance, their 
inputs, extrapolations, and/or assumptions [4, 5]. This uncer-
tainty about the (cost) effectiveness of new health technolo-
gies means HTA decision making is cognitively challenging 
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[2]. This situation is worsening: Recent pressures to grant 
market access earlier in the drug development process mean 
decisions are having to be made based on increasingly 
immature evidence [6–9] or on single-arm studies [10, 11]. 
If these uncertainties are not fully appreciated, decisions 
may be based on a biased view of expected incremental net 
benefit and the associated uncertainty. This in turn would 
lead to an increased risk of making a suboptimal decision, 
which can be described as opportunity losses, or potential 
losses in population health that could be averted with gather-
ing additional evidence [12].
Unfortunately, uncertainties are often not fully character-
ised in models [5]. We think this happens for two reasons: (1) 
undue emphasis on imprecision issues and (2) difficulty pre-
cisely expressing all uncertainty. The undue emphasis means 
that uncertainty about the quality and the generalisability of 
evidence to the setting in question is not always considered 
[13]. This is an omission that has long been recognised in the 
assessment of quality of evidence [14] and the risk assess-
ment literature [15, 16]. The GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) 
working group, for instance, highlighted the lack of focus 
on the quality of clinical evidence and proposed a system 
to acknowledge and even rate it [14, 17]. To the best of our 
knowledge, no tool for systematically identifying uncertainty 
about the quality of evidence used in models is currently 
available. Regarding (2), uncertainty is most completely char-
acterised with a full explicit probability distribution [4, 5, 18, 
19]. In theory, it may be possible to represent all uncertainty 
in this way, for example using methods to express expert 
opinion [20, 21] and/or structural uncertainty [22–24]. In 
practice, tight HTA timelines and resource constraints may 
be prohibitive. Other barriers include that people may not be 
able to express their beliefs in the form of probabilities [25] 
or that the distribution of the additional structural uncertainty 
parameter may be difficult to specify [13]. Therefore, most 
models do not incorporate all uncertainty in a quantitative 
manner and thus do not fully express the risk associated with 
a decision as a numerical value [13, 26].
In the worst case, the lack of systematic identification 
and assessment of all uncertainties present in models may 
result in a state of uncertainty ignorance, leaving decision 
makers unaware of the risk associated with a decision. But 
even where uncertainty information is present, it is usu-
ally scattered throughout reports, and decision makers are 
left with the cognitively challenging task of identifying all 
uncertainties and translating pieces of qualitative and quan-
titative uncertainty information into an overall assessment of 
uncertainty and risk [15]. A unified, comprehensive frame-
work for identifying uncertainties in models, assessing their 
impact, and reporting the results is therefore needed.
We developed a tool for systematically identifying, assess-
ing and reporting uncertainty in health economic submis-
sions. The paper is structured as follows: we first describe 
the development and validation of the TRUST (TRansparent 
Uncertainty ASsessmenT) tool. In Sect. 3, we present find-
ings from interviews and case studies and the final tool, as 
well as its place in the reimbursement decision-making pro-
cess. We conclude with a discussion and conclusion.
2  Development of TRUST
2.1  The Theoretical Framework
We developed a first version of the tool based on the litera-
ture on uncertainty and risk frameworks in HTA and risk 
assessment disciplines [14, 16, 18, 27–29]. Relevant litera-
ture was identified in a review of the literature on uncertainty 
frameworks. We used a pragmatic approach to this review 
and started with a citation search of a paper known to us 
[16]. We then checked the references of a recently published 
interdisciplinary literature review of uncertainty frameworks 
[18] for relevant uncertainty literature. Concepts surround-
ing uncertainty from the identified literature were checked 
for applicability and relevance in the HTA decision-making 
context by a group of researchers that drew upon experi-
ence in HTA decision making in the Netherlands and the 
UK. MJ, JG, BR, SG, and XP have been active members 
of a UK National Institute for Health and Care Excellence 
(NICE) evidence review group (ERG) and have built models 
that informed reimbursement decision making. SK has been 
a senior policy advisor of the Dutch Health Care Institute 
(ZIN) since 2012 and MJ a member of the scientific advisory 
committee of ZIN since 2013.
Key Points for Decision Makers 
In health economic decision making, uncertainty infor-
mation is currently not reported systematically, which 
leaves decision makers with the cognitively challenging 
task of translating pieces of qualitative and quantitative 
uncertainty information into an overall assessment of 
uncertainty and risk.
When considering uncertainty in health economic 
models, undue emphasis is placed on imprecision issues, 
which may lead to misrepresentation of uncertainty and 
ultimately of risk.
The TRansparent Uncertainty ASsessmenT (TRUST) 
tool enables the systematic identification, assessment, 
and reporting of uncertainties in health economic mod-
els, which may contribute to more informed and trans-
parent decision making in the face of uncertainty.
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2.1.1  Model Aspects
To systematically identify and assess uncertainty in mod-
els, it was necessary to establish the locations where uncer-
tainties could occur. Walker et al. [27] developed a “con-
ceptual basis for the systematic treatment of uncertainty 
in model-based decision support activities such as policy 
analysis, integrated assessment and risk assessment.” The 
authors identified the following locations: context (includ-
ing natural, technological, economic, social, and political 
representation), model (structure and technical), and inputs 
(driving forces, system data), parameters, and model out-
comes. Standard HTA dossier templates from the UK and 
Netherlands were used to inform more detailed descriptions 
of model aspects.
2.1.2  Sources of Uncertainty
Different uncertainty frameworks provide different taxono-
mies of uncertainty and use different terminology to describe 
uncertainty. Walker et al. [27] considered that uncertainty 
must be viewed as a three-dimensional concept: its nature 
(whether it is epistemic or aleatory), its level (from deter-
ministic knowledge to ignorance), and its locations (what is 
affected in the model-based assessment). Epistemic uncer-
tainty is that which could be reduced with further knowledge; 
aleatory uncertainty is caused by inherent variability [18]. In 
our paper, much like in the related health policy decision-
making literature [28], we focus on epistemic uncertainty, i.e. 
that which can be addressed in some form. The ‘levels’ in 
the Walker et al. [27] framework range from deterministic 
knowledge via statistical uncertainty (precision), scenario 
uncertainty (where the mechanism leading to different pos-
sible outcomes is not well understood), and recognised igno-
rance (scientific evidence for developing scenarios is weak) to 
total ignorance (unknown unknowns). These different levels 
were defined with the intention to call for different actions to 
address them. This list of levels is a pragmatic summary of the 
seven ‘sources’ of epistemic uncertainty previously identified 
[16]. The Walker et al. [27] framework has been adapted for 
the NUSAP (Numeral, Unit, Spread, Assessment and Pedi-
gree) approach to uncertainty assessment [29], which added 
methodological unreliability as a further type of uncertainty.
The GRADE working group outlined a broader frame-
work for assessing quality of evidence [17], establish-
ing five limitations that can lead to a downgrading of the 
quality: study limitations resulting in bias, inconsistent 
results (across studies), indirectness of evidence, impre-
cision, and publication bias [14, 17]. Van der Bles et al. 
[18] distinguished between ‘levels’ of direct and indirect 
uncertainty, where direct uncertainty pertains to impreci-
sion in estimates that can be communicated in quantitative 
terms, and indirect uncertainty relates to the quality of the 
underlying knowledge, which will typically be communi-
cated as a list of caveats (GRADE was named as an example 
tool that facilitates the assessment of indirect uncertainty). 
The International Society for Pharmacoeconomics and 
Outcomes Research–Society for Medical Decision Making 
(ISPOR–SMDM) taskforce report [28] makes a distinction 
between methodological uncertainty, parameter uncer-
tainty, stochastic uncertainty, heterogeneity, and structural 
uncertainty.
Our final selection of possible sources of uncertainty was 
informed by these taxonomies and based on the considera-
tion that, as different approaches are used in practice to man-
age uncertainty, it should be possible to match sources of 
uncertainty relevant to decision makers with an approach to 
dealing with uncertainty [27].
2.2  Expert Feedback
The TRUST tool was based on the theoretical framework 
just described and further developed based on several rounds 
of feedback from HTA experts. After the theoretical frame-
work was established, initial feedback was obtained by 
means of a discussion meeting with advisors of ZIN. The 
revised TRUST tool was presented at academic conferences 
(EUHEA 2018, Maastricht and IHEA 2019, Basel) and at 
further discussion meetings at ZIN, Maastricht University 
Medical Center, and Radboud University Medical Center. 
TRUST was presented during an HTA committee meeting 
for tomosynthesis for breast cancer population screening in 
the Netherlands. We conducted individual in-depth semi-
structured interviews with different international stakehold-
ers (N = 11) to finalise the content of the tool, validate it, 
and obtain insights into barriers to its use, user-friendliness, 
and feasibility. These stakeholders were chosen to repre-
sent the following stakeholder groups: HTA policy advisors 
(n = 2), independent academic advisors for HTAs (n = 4), an 
appraisal committee member (n = 1), and industry stakehold-
ers (n = 4, one working in a pharmaceutical company and 
three for HTA consultancies); convenience sampling was 
used to establish contact. The interviews were recorded, 
transcribed, and analysed by themes. The interview guide 
can be found in Appendix 1 in the Electronic Supplementary 
Material (ESM). Interviews were used to inform the selec-
tion of model aspects and sources of uncertainty to include 
in TRUST, terminology, and to highlight potential feasibility 
and usability issues.
2.3  Case Studies
The tool was tested for its validity and whether it ‘worked’ 
in practice by means of application in five retrospective HTA 
case studies on expensive medicines and one ongoing HTA, 
the latter being on tomosynthesis for breast cancer population 
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screening in the Netherlands. Four of the retrospective case 
studies were for ZIN in the Netherlands, and these were per-
formed by two researchers independently, who then compared 
notes to identify challenges in the use of TRUST and poten-
tial inter-rater variability. The fifth retrospective case study 
was a NICE appraisal (pembrolizumab for treating relapsed 
or refractory classical Hodgkin lymphoma); we present this 
here for illustration purposes. This application of TRUST was 
based on the information available in the article, ERG report, 
and company submission [11]. The case studies were selected 
based on convenience sampling: the ZIN referred us to the 
four retrospective Dutch case studies, and both the Dutch 
prospective study and the NICE study were projects in which 
members of our research team were involved.
3  Results
3.1  Findings from Stakeholder Interviews and Case 
Studies
Insights from stakeholder interviews were an important part 
of the development of this tool. The most important findings 
included the following (see Box 1 for more detail):
1. Keep it concise and simple
2. Rating uncertainty with a score may create a false sense 
of validity and be time consuming
3. Definitions and descriptions need to be clear
4. Time was the main barrier to the use of TRUST
The selected case studies represented a range of poten-
tial uncertainty issues encountered in health economic 
models (Table 1). They included appraisals of one screen-
ing technology (tomosynthesis for breast cancer population 
screening in the Netherlands) and five drugs (pembroli-
zumab for treating relapsed or refractory classical Hodgkin 
lymphoma in the England and Wales national health service, 
and lumacaftor/ivacaftor vs. best supportive care for treat-
ment of cystic fibrosis in patients aged ≥ 12 years homozy-
gous for the F508del mutation in the CFTR gene, nivolumab 
for treatment of non-small-cell lung cancer, rifaximin vs. 
lactulose alone for the treatment of recurrent episodes of 
manifest hepatic encephalopathy in patients aged ≥ 18 years, 
and eculizumab for the treatment of atypical haemolytic ure-
mic syndrome; the latter four were from the Netherlands).
3.2  The TRUST Tool
The TRUST tool integrates the outlined theoretical frame-
works on model aspects and sources of uncertainty in one 
taxonomy (Fig. 1). The rows present model aspects, and 
columns relate to sources of uncertainty (Appendix 2 in the 
ESM presents the full TRUST tool and updated versions can 
be found here: https ://osf.io/8eay7 /?view_only=90222 b3e31 
834e4 69c24 a92d5 87e24 7d).
Box 1  Interview and case study findings
ESM electronic supplementary material, GRADE Grading of Recommendations Assessment, Development and Evaluation; TRUST TRansparent 
Uncertainty ASsessmenT tool
1. Keep it concise and simple
 Although there were conflicting viewpoints on this (some respondents wished to add more response options or additional detail), the general 
feedback was that usability and interpretation of findings would improve with a version that was as concise as possible. The TRUST tool was 
simplified, for example by having dichotomous questions in the identification of sources of uncertainty in each model aspect, rather than pro-
viding three- or four-level response options. A summary was developed that only shows the main issues at one glance (Fig. 1 and Appendix 2 
in the ESM).
2. Rating uncertainty with a score may create a false sense of validity and be time consuming
 The first version of TRUST included a scoring system that was inspired by GRADE. This was intended to help assess, based on the different 
sources of uncertainty, the severity of the overall uncertainty associated with one model aspect. However, this caused multiple issues: there 
was significant inter-rater variability due to the subjective nature of assigning a score to the severity of uncertainty. Respondents considered 
that they would spend a long time trying to assign the score. This was confirmed in the case study applications. Rating uncertainty was also 
deemed potentially misleading: users might mistake the resulting score for a quantitative assessment or weight. As a result, a scoring system 
of uncertainty was not included in TRUST.
3. Definitions and descriptions need to be clear
 Respondents voiced difficulty with understanding the exact meaning of certain combinations of model aspects and sources of uncertainty. In 
response, we developed a key to the TRUST tool, with definitions and examples for each cell (Appendix 2 in the ESM).
4. Time is the main barrier to the use of TRUST
 The main barrier to its use was the perceived time it would take to complete TRUST. Opinions differed on this: some interviewees thought it 
was easy to complete while developing or reviewing a model; others stated it may present an additional burden for analysts and reviewers. 
Our case studies indicated that, after some of the issues with definitions and levels were resolved, TRUST could be completed within approxi-
mately 1 h when the dossier and model were already known. Application in retrospective case studies showed that completing TRUST could 
be difficult and time consuming when relying on information presented in pharmacoeconomic dossiers where uncertainty information was 
not easily accessible.
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Fig. 1  The TRUST tool part 1: identifying uncertainty
Table 1  Matrix of features observed in 6 case studies
Features Tomosynthesis Pembrolizumab Lumacaftor / ivacaftor Nivolumab Rifaximine Eculizumab
Features of case study
Drug X X X X X
Other technology X
ICER above threshold X X X X
Single arm studies X
Indirect treatment comparison X
Long-term extrapolation beyond avail-
able data
X X X X X
Clinical evidence from setting differ-
ent to decision problem
X X X X X X
Issues in clinical evidence due to 
intermediate outcomes
X
Issues in TRUST model aspects observed in case study
Issues with context / scope X X X
Issues with structural uncertainty X X
Issues with selection of evidence / 
review
X X X X
Issues with effectiveness X X X
Issues with relative effectiveness X X X X
Issues with adverse events X X X
Issues with HRQoL X X X X X
Issues with cost & resource use X X X X X
Issues with model implementation X X X
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3.2.1  Model Aspects
The selected model aspects included the ‘context/scope’, 
the ‘model structure’, ‘selection of evidence’ to inform the 
model, ‘model inputs’, its ‘implementation’, and ‘outcomes’. 
Our choice of model aspects was informed by Walker et al. 
[27]. Any deviations from this relate to the terminology used 
(to adapt to the target audience). With the ‘scope/context’ 
of the appraisal, we considered the definition of PICOTP 
(Patients, Intervention, Comparator, Outcomes, Time 
horizon, Perspective) of the decision problem. The aspect 
‘model structure’ is about the selection of health states and/
or events and how they relate to each other. ‘Selection of 
evidence’ refers to the review(s) informing the inputs of 
the assessment. We further subdivided the ‘model inputs’ 
section, distinguishing between transition probabilities/
time-to-event estimates/accuracy estimates; relative effec-
tiveness estimates; adverse events; utilities; and resource 
use and costs. By ‘model implementation’ we refer to its 
technical implementation and the calculations made. ‘Model 
outcomes’ are the reported results of the model.
3.2.2  Sources of Uncertainty
Summarising our findings, we consider that actionable 
sources of uncertainty include ‘transparency issues’, ‘meth-
odological issues’, ‘imprecision’, ‘bias and indirectness’, and 
‘unavailability’.
Transparency issues were included based on our experi-
ence and our interviews. We found that transparency issues 
were fairly common in models, and their descriptions and 
the addition of this item was deemed valuable in interviews. 
Ideally, such transparency issues can be addressed early on, 
with clarification requests. Based on the ISPOR–SMDM 
taskforce report and the NUSAP framework [28, 29], we 
considered uncertainty in methods as an additional source 
of uncertainty to be included in TRUST: by this, we refer to 
cases in which modelling methods are chosen that deviate 
from best practices or the reference case. This uncertainty 
could be addressed by means of clarification requests and 
scenario analysis.
The items of imprecision, bias and indirectness, and 
unavailability are issues with the evidence itself and shed 
light on its quality, credibility, and relevance. The item 
imprecision was non-controversial and was covered in all 
taxonomies, albeit with different terminology: parameter 
uncertainty in the ISPOR–SMDM taskforce report, direct 
uncertainty in van der Bles et al. [18], statistical uncer-
tainty (precision) in Walker et al. [27] and NUSAP [29], 
and imprecision in GRADE [14]. In TRUST, bias and indi-
rectness covers multiple aspects related to issues with the 
evidence. The GRADE items of ‘study limitations’, ‘indi-
rectness’, and ‘publication bias’ are all included here [14], 
as is indirect uncertainty per van der Bles [18] and structural 
uncertainty as per the ISPOR–SMDM taskforce report [28]. 
This source of evidence also includes scenario uncertainty 
per Walker et al. [27], as potential biases may be explored 
through scenarios when parameterisation is not an option. 
This is best addressed using scenario analysis or elicitation 
of expert opinion.
We disregarded GRADE’s inconsistent results, as we 
considered those to be issues with imprecision or bias and 
indirectness, which could respectively be parameterised or 
explored in scenarios [13]. Finally, we added unavailability 
to account for recognised ignorance per Walker et al. [27] 
and considered that such issues could be addressed with 
(extreme) scenario analysis, for example, informed by addi-
tional expert opinion.
3.2.3  Combination of Model Aspects and Sources 
of Uncertainty
In TRUST, combinations between aspects and sources of 
uncertainty are depicted in cells (Fig. 1, and Appendix 2 in 
the ESM). In these cells, we ask the following questions for 
each of the model aspects:
1. Is there a lack of clarity in presentation, description, or 
justification (transparency issue)?
2. Is there a violation of best research practices, existing 
guidelines, or the reference case (methodology issue)?
3. Is there an issue with particularly wide confidence inter-
vals, small sample sizes, or immaturity of data (impreci-
sion)?
4. Is there risk of bias or indirectness (bias and indirect-
ness)?
5. Is there a lack of data or insight (unavailability)?
These are dichotomous questions, with ‘yes’ or ‘no’ 
answers provided as response options. ‘Yes’ turns the cell 
red, and ‘no’ turns it green to enable a quick graphical over-
view of the main uncertainties in the assessment. A ‘not 
applicable’ option is also available. Furthermore, for ques-
tions 2–5, ‘intransparent’ can be selected when a transpar-
ency issue was reported when answering the first question. 
A ‘remarks’ column allows the analyst or reviewer to pro-
vide detail on the identified uncertainties (Appendix 2 in 
the ESM).
Some of the combinations are more intuitive than oth-
ers, and some may be downright impossible. Our experience 
from case studies and feedback from interviewees resulted 
in the following conclusions: imprecision issues are unlikely 
to arise within the model aspects of context/scope, model 
structure, and selection of evidence. Unavailability was 
deemed non-intuitive for the model aspect model structure. 
For the model aspect implementation, the relevant sources 
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of uncertainty were transparency issues and methods issues 
only, and, for model outcomes, we only considered trans-
parency issues, as the others would be an aggregation of 
uncertainties identified in the previous model aspects. The 
impossible (or at least unlikely) combinations are greyed out 
in TRUST. For all other possible combinations, we provide 
explanations and examples in Appendix 2 in the ESM.
3.3  Potential Impact of Uncertainties on Cost 
Effectiveness
The next step in TRUST is the assessment of the impact on 
cost effectiveness (Fig. 2). In this section of TRUST, the 
analyst can indicate whether the described uncertainty is 
appropriately reflected in the probabilistic sensitivity analy-
sis (PSA) (and hence expected value of perfect information). 
The next question asks whether the uncertainty is explored 
in scenario analysis.
Based on PSA and/or scenario analysis, we ask the final 
question: whether the identified uncertainty has an impact 
on cost effectiveness. Where an uncertain aspect is param-
eterised and reflected in the PSA, these results can be used 
to identify the most impactful uncertainties. Where neither a 
PSA nor scenario analyses are available, a subjective judge-
ment must be made. The response options to this question 
include ‘likely high impact’, ‘likely low impact’, ‘likely no 
impact’, and ‘unknown’. The responses ‘likely high impact’ 
and ‘unknown’ turn these cells red. An application of the 
TRUST tool is shown in Box 2 and Table 2.
3.4  Proposed Use of TRUST in the Decision‑Making 
Process
Based on the discussions with stakeholders, we think of the 
process of dealing with uncertainty in HTA as comprising 
the following three phases, with specific courses of action 
and roles pertaining to each (Fig. 3): phase I, identify; phase 
II, explore impact; and phase III, manage.
In phase I, we suggest first identifying issues with trans-
parency and methods (phase Ia). These can best be addressed 
by writing or requesting clarifications, redoing any analyses 
that were not methodologically sound, and/or performing 
scenario analysis on the methodological uncertainties. In 
phase Ib, uncertainties caused by imprecision, bias and 
indirectness, and/or unavailability are identified. These can, 
respectively, be addressed by PSA/deterministic sensitivity 
analysis and plausible and/or extreme scenario analysis. In 
addition, it is possible that issues with bias and indirectness, 
unavailability, and methodological issues are parameterised 
and therefore reflected in the PSA.
Phase II explores the impact of uncertainty on, first, cost 
effectiveness (IIa) and then risk (IIb). An overview of high-
impact uncertainties can aid the design of potential research 
schemes, which can be assessed using established methods 
Fig. 2  The TRUST tool part 2: 
assessing the impact of uncer-
tainties on cost effectiveness
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[26]. When a financial scheme is an option, phase II is repeated 
with the scheme incorporated in the modelling. Phases I and II 
are within the responsibility of the analyst/reviewer.
Lastly, the decision maker will appraise the risk in 
phase III and determine which, if any, risk-management 
options such as Managed Entry Agreement (MEA) schemes, 
are most suitable and arrive at a recommendation. The 
TRUST tool is positioned in phases I and IIa.
Box 2  Application of TRUST in a case study
NICE National Institute for Care and Excellence, OS overall survival, PSA probabilistic sensitivity analysis, SCT stem cell transplant
NICE appraisal titled ‘Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma’ (2018)
Pembrolizumab was compared with standard of care in patients who did and did not receive prior autologous SCT.
This NICE appraisal suffered from a lot of uncertainty (Table 2).
Most impactful uncertainty locations: model structure, transition probability and relative effectiveness estimates.
Model structure: the main uncertainty was that the time at which patients would receive allogeneic SCT was modelled as a fixed time point 
(bias). Not included in PSA or scenario analysis (alternative time point submitted later upon request).
Transition probability estimates: distributions to model OS were selected without appropriate justification (methods). Not included in the PSA 
but explored in scenario analysis.
The company deemed their own trial to be immature for modelling OS (imprecision), and the estimation of post-allogeneic SCT OS was based 
on a study that included 13 patients (imprecision). Both included in PSA.
Relative treatment effectiveness: using a naïve comparison for two single-arm studies (methods and bias). Not in PSA, but in scenario with 
matched-adjusted indirect comparison.
Comparator data had a mixed population of patients who did and did not receive prior autologous SCT (bias). Not explored in PSA or scenarios 
(scenario with alternative data for one population submitted later upon request).
Unknown impact on cost effectiveness: context/scope and selection of evidence.
Context/scope: comparators were omitted, best supportive care (unavailability of data) and nivolumab due to direction by NICE (unavailability 
and methods). No PSA or scenarios.
Selection of evidence: a list of health economic publications on this topic was not provided (transparency). No PSA or scenarios.
Conclusions:
1. Example of the increasing number of applications for reimbursement based on single-arm evidence and immature survival data.
2. Most impactful uncertainties were issues with bias and indirectness, methods and imprecision and were not always included in the PSA.
3. Reaching a reimbursement decision under such circumstances is potentially associated with a significant risk.
Table 2  Illustration of TRUST in pembrolizumab for Hodgkin lymphoma case study
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4  Discussion
We developed the TRUST tool for systematically identify-
ing, assessing, and reporting uncertainty in health economic 
models. To the best of our knowledge, this is the first tool 
to enable the transparent identification, assessment, and 
reporting of uncertainties in different model aspects in one 
place and the first to highlight the different sources of uncer-
tainties. This is important because our experience and the 
literature indicate shortcomings in how uncertainty informa-
tion is currently presented in health economic submissions 
[13]. Furthermore, we hope that TRUST will, in the future, 
prevent uncertainties due to bias, indirectness, and unavail-
ability from being overlooked, an issue that may cause a 
misrepresentation of risk. Implementation of TRUST in six 
case studies showed that some of the most impactful uncer-
tainties were issues not with imprecision but with bias and 
indirectness. A re-thinking of how we consider uncertainties 
in models appears warranted, especially given that increased 
leniency in evidential requirements and handling of evidence 
has been observed, at least in the UK setting [30]. Knowl-
edge about sources of uncertainty is also important because 
it helps recognise that different sources of uncertainty may 
call for different types of analyses. We hope this tool will 
contribute to the systematic identification, assessment, and 
reporting of uncertainties in HTA and therefore to more 
informed and transparent decision making in the face of 
uncertainty.
TRUST borrows from a range of uncertainty frameworks 
in different disciplines, which we view in two categories: 
those within and those outside the field of health economics. 
Compared with existing uncertainty frameworks outside the 
field of health economics [16, 18, 27, 29], TRUST has been 
adapted to match the needs of HTA analysts and decision 
makers, for instance with a focus on epistemic uncertainty 
and it being aligned with typical structures of health eco-
nomic reporting. TRUST adds to the frameworks inside the 
field of health economics [5, 28] by considering different 
Fig. 3  The process of uncertainty and risk assessment. DSA deterministic sensitivity analysis, EVPI Expected Value of Perfect Information, 
MEA Managed Entry Agreement scheme, PSA probabilistic sensitivity analysis
214 S. E. Grimm et al.
sources of uncertainty and requiring an assessment for each 
model aspect in one place. Where other uncertainty tools 
have already been completed for a certain decision prob-
lem, for instance, a GRADE assessment is available for the 
studies informing relative treatment effectiveness, results of 
this can be used to fill in TRUST, if consideration is given to 
whether the decision problem settings are truly equivalent 
and the source is trustworthy. TRUST also complements 
existing tools on model validation [31, 32]. Assessing uncer-
tainty is to be seen as a separate albeit related exercise to val-
idating a model or model aspects. A model that is rigorously 
validated and even considered valid will still suffer from 
uncertainty. We therefore wish to caution against assuming 
uncertainty is resolved when validation has taken place.
A strength of this work is that TRUST has its foundation 
in the uncertainty framework literature. The content of this 
tool was further validated through feedback from experts 
with different backgrounds relevant to the HTA decision-
making process during its development. Experts thought this 
tool was of potential value in uncertainty assessment but 
thought the proof would be in its use in actual decision mak-
ing. Application in six real-world HTA case studies served 
as further validation: all uncertain model aspects could be 
registered without difficulty, and inter-rater variability was 
reduced after the tool’s amendment. A caveat is that these 
six case studies may not represent all the unique features that 
may be observed in reimbursement applications; however, 
they did cover, amongst other features, single-arm studies, 
the use of indirect treatment comparisons, clinical evidence 
from different settings, structural uncertainty, long-term 
extrapolation beyond the available follow-up, issues related 
to the use of intermediate outcomes, and how these related 
to health states (Table 1).
We acknowledge that the part of TRUST concerning 
the impact of uncertainties on cost effectiveness may elicit 
subjective answers, especially when uncertainty is not suffi-
ciently explored through PSA or scenario analysis. However, 
we wish to highlight that, where these considerations are 
not made explicit, they will be made implicitly, and poten-
tially in a non-systematic and opaque fashion. We consider 
an explicit subjective judgement to be superior to no judge-
ment at all or to a subconscious judgement that may implic-
itly drive decision making. We recognise that representing 
the impact of uncertainty can be challenging, both meth-
odologically and in terms of time constraints. We argue for 
parameterising uncertainty as much as possible, and, if this 
is infeasible, we propose representation of uncertainty in 
terms of ranges of the incremental cost-effectiveness ratio 
or net benefit statistics. In addition, results from plausible 
and extreme scenario analysis and qualitative statements 
should be reported [13, 18]. A limitation of this work is 
the transferability of TRUST to settings other than the UK 
or the Netherlands. However, the tool can be tweaked in 
terms of the model aspects covered and response options if 
interested individuals wish to apply it outside these settings 
and believe that model aspects do not cover all aspects con-
sidered. We believe the sources of uncertainty to be fairly 
universal and grounded in the literature so would not advise 
tweaking those without good justification.
A further limitation relates to the added time it may take 
to use TRUST. Interviewees suggested that, once in the 
process of reviewing evidence submitted by companies, or 
indeed developing an evidence submission, it might only 
take an hour to complete. However, we also found that com-
pletion could be more difficult and therefore time consum-
ing if the evidence was not easily accessible. If it was not 
possible to complete TRUST within the review process, we 
consider this to be a potentially important finding that should 
be communicated, as it may mean that the evidence and the 
model could not be fully assessed. Furthermore, if explicit 
consideration of uncertainty is desired in a world that relies 
on increasingly sparse evidence, processes may have to be 
adjusted to allow for these additional analyses.
Knowledge of uncertainty is crucial for risk management 
[15, 18]. In the process of HTA, communication of uncer-
tainty is therefore key, but is also a challenge. The TRUST tool 
can help identify and report uncertainty, but effective commu-
nication to decision makers may require effective summaries 
and visualisation of uncertainty and risk. Communicating 
uncertainty does not necessarily undermine trust [18] but can 
indeed be appreciated by the target audience [33]. It can and 
should, in our opinion, be viewed as a duty of science [34], 
as Høeg expressed, “That is what we meant by science. That 
both question and answer are tied up with uncertainty, and 
that they are painful. But that there is no way around them. 
And that you hide nothing; instead, everything is brought out 
into the open” [35]. Further research should therefore be per-
formed on the communication of results from TRUST to com-
mittees and decision makers, considering whether it changes 
perceptions and/or behaviours [18, 36]. Here, both outcomes 
would be desirable: we wish to effect change in the percep-
tion of uncertainty and risk in an appraisal; ideally, this would 
translate into better risk management. Further research should 
also focus on the link between the TRUST tool outcomes and 
risk-management options.
5  Conclusion
The TRUST tool enables the systematic identification, 
assessment, and reporting of uncertainties in health eco-
nomic decision models and may contribute to more informed 
and transparent decision making in the face of uncertainty. 
Further research is needed on uncertainty and risk commu-
nication and the link to risk-management options.
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